Filing Details
- Accession Number:
- 0000914475-25-000024
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-04 17:45:18
- Reporting Period:
- 2025-01-31
- Accepted Time:
- 2025-02-04 17:45:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1965808 | Ingrid Delaet | 12780 El Camino Real San Diego CA 92130 | Chief Regulatory Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-01-31 | 801 | $0.00 | 3,308 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-01-31 | 422 | $153.05 | 2,886 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-02-03 | 1,179 | $0.00 | 4,065 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-03 | 623 | $149.29 | 3,442 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restriced Stock Unit | Disposition | 2025-01-31 | 801 | $0.00 | 801 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2025-02-03 | 1,179 | $0.00 | 1,179 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 801 | No | 4 | M | Direct | ||
| 0 | No | 4 | M | Direct |
Footnotes
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.91 to $154.35. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 800 shares on January 31, 2023, vested as to 800 shares on January 31, 2024, vested as to 801 shares on January 31, 2025, and will vest as to 801 shares on January 31, 2026, subject to the terms and conditions of the award.
- This RSU was granted to the Reporting Person on February 1, 2021. In accordance with the terms of the RSU, the award vested as to 1,180 shares on February 1, 2022, vested as to 1,179 shares on February 1, 2023, vested as to 1,179 shares on February 1, 2024, and vested as to 1,179 shares on February 1, 2025, subject to the terms and conditions of the award.
Billionaire Hedge Funds
